Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Diluted Average) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $64.5 million as the latest value for Q3 2024.

  • For Q3 2024, Shares Outstanding (Diluted Average) rose 2.35% year-over-year to $64.5 million; the TTM value through Sep 2024 reached $64.5 million, up 2.35%, while the annual FY2023 figure was $63.3 million, 20.58% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $64.5 million in Q3 2024 for Crescent Biopharma, roughly flat from $64.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $64.5 million in Q1 2024 and bottomed at $45.7 million in Q4 2020.
  • Average Shares Outstanding (Diluted Average) over 5 years is $56.7 million, with a median of $52.5 million recorded in 2022.
  • Year-over-year, Shares Outstanding (Diluted Average) increased 23.17% in 2023 and then increased 0.1% in 2024.
  • Crescent Biopharma's Shares Outstanding (Diluted Average) stood at $45.7 million in 2020, then rose by 12.54% to $51.5 million in 2021, then increased by 2.1% to $52.5 million in 2022, then rose by 20.58% to $63.3 million in 2023, then increased by 1.79% to $64.5 million in 2024.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $64.5 million, $64.5 million, and $64.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.